Arrowhead Pharmaceuticals Inc
NASDAQ:ARWR
Arrowhead Pharmaceuticals Inc
Accumulated Depreciation
Arrowhead Pharmaceuticals Inc
Accumulated Depreciation Peer Comparison
Competitive Accumulated Depreciation Analysis
Latest Figures & CAGR of Competitors
Company | Accumulated Depreciation | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Arrowhead Pharmaceuticals Inc
NASDAQ:ARWR
|
Accumulated Depreciation
-$50m
|
CAGR 3-Years
-38%
|
CAGR 5-Years
-36%
|
CAGR 10-Years
-30%
|
|
Abbvie Inc
NYSE:ABBV
|
Accumulated Depreciation
-$6.7B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-4%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Accumulated Depreciation
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Amgen Inc
NASDAQ:AMGN
|
Accumulated Depreciation
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Accumulated Depreciation
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Accumulated Depreciation
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Arrowhead Pharmaceuticals Inc's Accumulated Depreciation?
Accumulated Depreciation
-50m
USD
Based on the financial report for Mar 31, 2024, Arrowhead Pharmaceuticals Inc's Accumulated Depreciation amounts to -50m USD.
What is Arrowhead Pharmaceuticals Inc's Accumulated Depreciation growth rate?
Accumulated Depreciation CAGR 10Y
-30%
Over the last year, the Accumulated Depreciation growth was -38%. The average annual Accumulated Depreciation growth rates for Arrowhead Pharmaceuticals Inc have been -38% over the past three years , -36% over the past five years , and -30% over the past ten years .